PRIME MEDICINE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.99 USD | -2.60% |
|
-15.75% | -32.39% |
Presenter SpeechSalveen Richter (Analysts)Great. Good afternoon, and thank you for joining us ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Prime Medicine, Inc. is a biotechnology company engaged in creating and delivering the gene editing therapies to patients. It deploys its Prime Editing platform, a gene editing technology, to develop a new class of differentiated, one-time genetic therapies. It is engaged in developing Prime Editors as a new class of therapeutics with transformative potential to expand the application of curative precision genetic medicines. It has built a diversified portfolio of investigational therapeutic programs organized around core areas of focus, namely hematology and immunology, liver, lung, ocular and neuromuscular. The programs within its other areas of focus are on earlier stages of preclinical development and include Liver programs, such as Wilson's disease and glycogen storage disease 1b; Lung program, such as Cystic fibrosis; Ocular program, such as Retinitis pigmentosa caused by Rhodopsin mutations, and Neuromuscular programs, including Friedreich's ataxia and myotonic dystrophy type 1.
Calendar
05/08/2024
- Q2 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
5.99
USD
Average target price
14.18
USD
Spread / Average Target
+136.76%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -32.39% | 69Cr | |
| +15.19% | 12TCr | |
| +19.91% | 11TCr | |
| +8.24% | 2.36TCr | |
| -19.80% | 2.04TCr | |
| -16.19% | 1.65TCr | |
| -13.45% | 1.64TCr | |
| -44.35% | 1.56TCr | |
| +66.67% | 1.52TCr | |
| +2.13% | 1.35TCr |
- Stock Market
- Equities
- PRME Stock
- News Prime Medicine, Inc.
- Transcript : Prime Medicine, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 02
